Altucher said today on Twitter that his favorite pick is Trovagene (TROV) and his second favorite is VRNG. Check out the IR presentation on Trovagene website. They figured out how to diagnose cancer, infectious diseases, hpv, etc in urine. URINE! They can also do transplant monitoring and pre-natal stuff. All cancer patients are always cancer patients. They always need monitoring and TROV is rolling out new urine based cancer diagnostic tests now. The entire old management team from Sequenom just took over TROV to commercialize the cancer tests.......$60 mil co that could go up 500-1000%. tons of elite people jumped behind the co in the past year. check the board of directors and advisory board
go see altucher's seekingalpha article about Trovagene. go search for his twitter post about 'TROV' and 'VRNG'
"@jaltucher: @WesStull 1. $TROV 2.$VRNG and 3 others i cant say yet"//This is JAMES ALTUCHER's answer to-YOUR TOP 5 GROWTH STOCKS IN ORDER.
James Altucher @jaltucher
@WesStull $TROV $VRNG and 3 others i cant say yet
The investor presentation on the trovagene website ir page really is impressive. The CEO talks for 30 minutes about why trove is a game changer for molecular diagnostics. People should check it out. I see vrng popping to $4.75 after the file lawsuit against Microsoft and yahoo
Wondering about this one. 58K volume at 1:00 p.m., and a recommendation by James Altucher. Those are two things working against any poor judgement I will have made if I hadn't bought into Altucher's "pumping" of VRNG leading to the trial. His predictions were ALL wrong. GOOG did not settle, It did make it to trial, the trial was seen through to a verdict, the damages were essentially a scam, and the stock price, as we can clearly see, shows no indications of reaching into the $30's, $20's, $12, $10, $8; and hell, it is struggling at $3.50 now. It has been close to 3 full days since the verdict and the company has been dented. Shareholders are now hanging onto the thread of hope that the joke of a number revealed in the damages was a mathematical error on the part of the jury and the Judge will suddenly jump out with groundbreaking news. I call #$%$ Now; back to $TROV. I will not make the same mistake on this one. I've invested in $S. Granted, Sprint's growth has been slow, but at least it is growth-driven rather than emotion-driven. I will not invest my money at the "pump" advice of some wealthy pumper who is trying to score a quick buck off of the reactive emotions of investors. My money is on CLWR and S. At least there is some transparency in their practices that allow me to make sound investment decisions and MAKE money! Thoughts?
P.S. I wish there was a #$%$ NO" option with a radio button at the bottom of this posting!
Trov will really start moving higher as soon as the launch their first cancer test in q4. Last week they filed an 8k that had a presentation in it that showed the schedule for the launch of their cancer tests based on body parts. Very impressive
Altucher always has good picks with good potential. They don't always work out. Study on your own why he likes trov and make your own conclusions. I think he sees trov entering a massive industry and all the elite people jumping behind the technology as proof that it works
Make up your own mind about Trovagene. It is STRONGLY recommended that you listen to the 30 minute presentation on the Trovagene IR page in their site. Tony Schuh is awesome CEO for Trovagene. He was the CEO of Sequenom and brought his whole senior management team from Sequenom to Trov for a reason. The reason is that the tech works. The chairman of Trovagene is Thomas Adams the founder of $3 billion dollar Genprobe. Look at all the elite people on their management team, advisory board, and executive board. All these people joined TROV in the past year - for a reason. The tech works and is revolutionary